JP2008517943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517943A5 JP2008517943A5 JP2007538156A JP2007538156A JP2008517943A5 JP 2008517943 A5 JP2008517943 A5 JP 2008517943A5 JP 2007538156 A JP2007538156 A JP 2007538156A JP 2007538156 A JP2007538156 A JP 2007538156A JP 2008517943 A5 JP2008517943 A5 JP 2008517943A5
- Authority
- JP
- Japan
- Prior art keywords
- histidine
- use according
- cancer
- cysteine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62109104P | 2004-10-25 | 2004-10-25 | |
| PCT/US2005/038317 WO2006047485A2 (en) | 2004-10-25 | 2005-10-25 | Methods for lowering hif-1 mediated gene expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008517943A JP2008517943A (ja) | 2008-05-29 |
| JP2008517943A5 true JP2008517943A5 (enExample) | 2008-12-11 |
Family
ID=36228364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538156A Withdrawn JP2008517943A (ja) | 2004-10-25 | 2005-10-25 | Ｈｉｆ−１媒介遺伝子発現を低下させる方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080045463A1 (enExample) |
| EP (1) | EP1814570A2 (enExample) |
| JP (1) | JP2008517943A (enExample) |
| AU (1) | AU2005299482A1 (enExample) |
| CA (1) | CA2585268A1 (enExample) |
| WO (1) | WO2006047485A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010024908A1 (en) * | 2008-08-26 | 2010-03-04 | Fibrogen, Inc. | Methods for treatment of multiple sclerosis |
| WO2012082765A2 (en) * | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| WO2012135397A2 (en) * | 2011-03-29 | 2012-10-04 | Lisanti Michael P | Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome |
| EP3113766B1 (en) * | 2014-03-05 | 2021-04-07 | Evan C. Unger | Fractionated radiotherapy and chemotherapy with an oxygen therapeutic |
| JP7160683B2 (ja) * | 2016-04-29 | 2022-10-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 術後癒着の予防及び治療のための方法及び組成物 |
| JP7280470B2 (ja) * | 2019-11-29 | 2023-05-24 | 慶應義塾 | 特定アミノ酸またはアミノ酸様物質による低酸素応答制御 |
| CA3218944A1 (en) * | 2021-05-16 | 2022-11-24 | Slavica TUDZAROVA-TRAJKOVSKA | Methods and compositions for treating cardiovascular disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843481A (en) * | 1994-01-18 | 1998-12-01 | Mount Sinai Hospital Corporation | Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof |
| US6566088B1 (en) * | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| US20050096370A1 (en) * | 2003-04-07 | 2005-05-05 | Bizbiotech Co., Ltd. | Method for inhibiting tumor angiogenesis and tumor growth |
| EP1709175A2 (en) * | 2003-12-03 | 2006-10-11 | Corgentech, Inc. | Hif oligonucleotide decoy molecules |
-
2005
- 2005-10-25 CA CA002585268A patent/CA2585268A1/en not_active Abandoned
- 2005-10-25 WO PCT/US2005/038317 patent/WO2006047485A2/en not_active Ceased
- 2005-10-25 JP JP2007538156A patent/JP2008517943A/ja not_active Withdrawn
- 2005-10-25 AU AU2005299482A patent/AU2005299482A1/en not_active Abandoned
- 2005-10-25 US US11/666,229 patent/US20080045463A1/en not_active Abandoned
- 2005-10-25 EP EP05851246A patent/EP1814570A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Autophagy, a double-edged sword in anti-angiogenesis therapy | |
| Sugahara et al. | Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease | |
| Semenza | Hypoxia-inducible factors: roles in cardiovascular disease progression, prevention, and treatment | |
| Zhang et al. | The physiological functions of iron regulatory proteins in iron homeostasis-an update | |
| Razani et al. | Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities | |
| Tamura et al. | A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors | |
| Guo et al. | Silver@ Prussian Blue Core–Satellite Nanostructures as Multimetal Ions Switch for Potent Zero-Background SERS Bioimaging-Guided Chronic Wound Healing | |
| US9447418B2 (en) | Pro- and anti-angiogenic treatments | |
| JP2008517943A5 (enExample) | ||
| BR112013003186A2 (pt) | composições e métodos para tratamento de doença cardiovascular | |
| Ding et al. | A bioresponsive diselenide-functionalized hydrogel with cascade catalytic activities for enhanced local starvation-and hypoxia-activated melanoma therapy | |
| Barylski et al. | Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome | |
| Trichonas et al. | Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy in the rat 50/10 model | |
| Laurila et al. | EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models | |
| WO2015089495A3 (en) | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders | |
| Gomez-Sintes et al. | Chaperone-mediated autophagy and disease: Implications for cancer and neurodegeneration | |
| C. Chan et al. | Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase | |
| Wu et al. | NIR driven catalytic enhanced acute lung injury therapy by using polydopamine@ Co nanozyme via scavenging ROS | |
| Yu et al. | Overexpression of Smad7 suppressed ROS/MMP9-dependent collagen synthesis through regulation of heme oxygenase-1 | |
| Sun et al. | Multienzymatic Hybrid Metalloenzymes Triggering Cascade Reactions-Regulated Tumor Redox Homeostasis and Immunosuppressive Microenvironment for Catalytic Immunotherapy | |
| Aggarwal et al. | Effect of cisplatin on renal iron homeostasis components: implication in nephropathy | |
| Chen et al. | Circ_0014359 promotes oral squamous cell carcinoma progression by sponging miR-149 | |
| El-Arabey | Sex and age differences related to renal OCT2 gene expression in cisplatin-induced nephrotoxicity | |
| WO2012127289A8 (en) | R2r1/2 in diagnosis and therapy | |
| JP2007502855A5 (enExample) |